Clinical evidence, disclosure failures, and the transition to Filana Therapeutics.

Subsys marketing, criminal accountability, and the limits of financial recovery.

Prescribing incentives, specialty pharmacies, and patient-assistance boundaries.

Manufacturing integrity, truthful data, and dependable generic access.

Disclosure fairness, women's health products, and the royalty transition.

Daraprim pricing and the exclusion of generic competition.

Pricing, Philidor, and the disclosure of growth.

Promotion, safety reporting, and financial incentives.

EpiPen Pricing, Public Rebates, and Disclosure.

Promotion, Competition, and Medicine Access.

Product Switching, Patent Review, and Access to Competition.

Generic Price Fixing, Remedies, and Reliable Access.

Acthar Pricing, Public Rebates, and Accountability After Restructuring.

Biologic competition, patient assistance and negotiated prices.

Generic entry, opioid marketing and corporate succession.

Generic competition and the Copaxone access record.

Hepatitis C pricing, HIV promotion, and the path to long-acting prevention.

Promotional enforcement, public-payer pricing, and an evolving competition case.

Historical Promotion Cases and the Transition to Generic Access.

Insulin, GLP-1 Pricing, and Access Accountability.

Promotion Accountability and the Reliability of Access Information.

Reverse-Payment Settlements, Generic Competition, and Corporate Succession.

Marketing integrity, generic competition, and corporate change.

Reimbursement integrity and the meaning of insulin affordability.

Prescribing integrity and access to oncology innovation.

Medicine quality, reliable supply, and pricing commitments.

Pricing, Assistance, and Competition in Oxybate Medicines.